MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
As of May 15, 2025, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis continues to demonstrate a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated to date in this heavily pre-treated population. 1 Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months. 2-3
'It is gratifying to see that our treatment further extends lives for these hard-to-treat patient populations, especially in third-line NSCLC treatment where patients are most resistant to therapy,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape.'
MAIA's multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
42 minutes ago
- Business Upturn
MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025
Salt Lake City, Aug. 12, 2025 (GLOBE NEWSWIRE) — Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Joint comfort and flexibility are vital for maintaining an active, independent lifestyle — whether it's enjoying daily walks, engaging in sports, or simply moving through the day without stiffness. The conversation around joint health is shifting toward preventative, natural options that align with long-term wellness goals in 2025. MobilityMD has emerged as part of this dialogue, offering a joint support formula built on a foundation of purity, ingredient transparency, and thoughtful formulation. While it avoids overpromising results, the supplement positions itself within the growing category of wellness products designed to complement healthy movement and an active lifestyle. Discover how MobilityMD's carefully selected ingredients are shaping the conversation around joint wellness in 2025. SECTION 1: WHY INTEREST IN 'THE SECRET, PURE INGREDIENT TO SUPPORT HEALTHY JOINTS' IS SURGING IN 2025 Joint health has become a central focus for people of all ages in 2025 — from active adults looking to preserve mobility to those seeking extra support for daily comfort. This growing attention is reflected in online search trends, with Google reporting increases in queries like 'natural joint support,' 'supplements for flexibility,' and 'best ingredients for mobility.' The public is no longer just looking for quick fixes; instead, there is heightened curiosity around long-term strategies that integrate into a balanced, healthy lifestyle. Part of this shift comes from the broader wellness movement, where consumers prioritize transparency, clean sourcing, and minimal additives in the products they choose. Social media platforms, wellness podcasts, and fitness forums are filled with discussions comparing ingredient profiles, sharing personal experiences, and evaluating which formulas fit into individual health routines. MobilityMD has entered this conversation not by making sweeping claims, but by highlighting its focus on purity and thoughtful formulation. This aligns with the expectations of today's wellness-conscious consumers, who often seek products designed to complement an active lifestyle without relying on unnecessary fillers or synthetic additives. SECTION 2: MOBILITYMD'S INGREDIENT-FIRST RESPONSE TO THESE TRENDS MobilityMD was developed with a clear focus on sourcing and formulation choices that align with the modern consumer's expectations for clean, purposeful supplementation. Rather than relying on heavily processed or synthetic compounds, the formula incorporates naturally derived ingredients that have been historically discussed for their association with mobility and joint comfort. Each component is chosen with the intent to complement an active lifestyle while avoiding unnecessary additives that do not contribute to the product's purpose. The ingredient selection process emphasizes purity and transparency. This includes providing clear information about sourcing, composition, and function so that consumers can make informed choices about what they put into their bodies. The formulation also considers how different ingredients work together, aiming for a balanced profile that fits into a variety of health routines — from daily wellness habits to more targeted mobility-focused regimens. Importantly, MobilityMD avoids making direct medical claims. Instead, it positions itself as part of a broader wellness strategy, one that supports consumers in pursuing movement-friendly lifestyles while staying mindful of ingredient integrity. Discover how MobilityMD's ingredient transparency reflects the growing demand for cleaner, more purposeful joint support supplements. SECTION 3: INGREDIENT SPOTLIGHT – WHAT'S INSIDE THE FORMULA The foundation of MobilityMD lies in a carefully curated selection of naturally derived ingredients, each frequently discussed in wellness circles for their historical associations with joint comfort and mobility. While the product avoids making direct health claims, it draws on a blend that reflects both tradition and modern supplement formulation trends. Key components often include botanical extracts that have been explored for their potential to support overall wellness, minerals that play a role in maintaining balanced body functions, and naturally occurring compounds that have been studied for their relevance to healthy aging. Each ingredient is chosen with attention to purity, potency, and its ability to integrate seamlessly into a daily health regimen. MobilityMD also emphasizes the importance of what's left out of the formula. There are no unnecessary fillers, artificial colors, or synthetic preservatives — a choice that resonates with consumers who are mindful of every element they consume. This focus on clean composition positions the supplement within the growing category of wellness products designed for individuals who prioritize ingredient integrity as much as potential functional benefits. SECTION 4: WHAT REDDIT, PODCASTS & TIKTOK CREATORS ARE SAYING Conversations about joint health supplements have expanded well beyond traditional advertising channels in 2025. On Reddit, wellness and fitness communities are filled with discussions about ingredient quality, transparency, and the importance of long-term consistency in supplementation. Users frequently share their experiences with products that align with clean-label trends, and MobilityMD has been mentioned in threads that focus on naturally derived joint support options. Podcasts in the health and wellness space often highlight how consumers are becoming more discerning about supplement choices. Guests on these shows frequently emphasize reading ingredient labels, understanding sourcing, and looking for products that complement an active lifestyle. MobilityMD's ingredient-focused approach aligns with these ongoing discussions, making it a relevant part of broader wellness dialogues. On TikTok, creators in the fitness, yoga, and lifestyle categories are producing short-form content around joint-friendly routines, mobility exercises, and supplement habits that fit into a balanced regimen. While these creators don't make specific claims about results, they often showcase how clean-label supplements can be integrated alongside movement practices to support overall wellness. Learn why MobilityMD is appearing in more conversations about clean, transparent joint support in 2025. SECTION 5: WHO MIGHT BE DRAWN TO THIS TYPE OF SUPPLEMENTATION IN 2025 MobilityMD appeals to a wide range of individuals who prioritize maintaining joint comfort and flexibility as part of their overall wellness goals. Active adults, including those who enjoy walking, hiking, yoga, or recreational sports, may be drawn to the idea of a supplement that aligns with their lifestyle without unnecessary additives. Professionals who spend long hours sitting or standing may also find the clean-label approach appealing, as they look for ways to support movement and ease in daily routines. Similarly, older adults seeking to remain active and independent often look for supplements with a transparent ingredient list that avoids synthetic fillers or artificial preservatives. The eco-conscious and health-conscious crowd is another natural audience for MobilityMD. For these individuals, supplement choice is about more than potential functional benefits — it's about knowing that the formula is built on pure, purposeful components. This aligns with the broader wellness movement of 2025, where consumers increasingly value products that support their personal health goals while also reflecting their ethical and environmental values. SECTION 6: EMERGING WELLNESS & PERFORMANCE INNOVATION – 2025 MARKET REFLECTIONS The wellness and supplement market in 2025 reflects a distinct shift toward ingredient transparency, clean-label formulations, and products that fit seamlessly into long-term health routines. Consumers are increasingly skeptical of overpromising claims and are instead prioritizing supplements that are clear about their composition and intended role in a balanced lifestyle. This has created a strong market for products like MobilityMD, which position themselves as part of a broader wellness toolkit rather than a one-step solution. This trend is driven in part by the rise of self-education in health and nutrition. With more information available online than ever before, people are researching ingredients, comparing labels, and making purchasing decisions based on both scientific discussion and personal values. Social media platforms, wellness blogs, and community forums all contribute to this heightened awareness, creating a consumer base that demands higher standards from supplement brands. Within this environment, joint health remains a high-priority category. As active lifestyles, desk-based work, and healthy aging all intersect, the demand for products that align with everyday mobility needs continues to grow. MobilityMD's focus on purity and purposeful formulation allows it to stand out in a competitive market where consumers are looking for supplements that are as trustworthy as they are functional. Discover why MobilityMD is part of the new wave of clean, ingredient-first wellness products in 2025. SECTION 7: THE PUBLIC DEBATE AROUND JOINT HEALTH SUPPLEMENTS – SIGNALS, SKEPTICISM, AND SATURATION The conversation around joint health supplements in 2025 is both active and divided. Supporters often point to the importance of staying proactive with mobility support, highlighting the role of clean, naturally derived ingredients in long-term wellness routines. They value brands that offer transparency and avoid unnecessary additives, seeing these products as part of a broader strategy to maintain active, comfortable movement. Skeptics, however, question whether supplements are necessary for everyone and emphasize the need for realistic expectations. They often stress that lifestyle habits — such as regular movement, balanced nutrition, and proper hydration — form the foundation of joint health, with supplementation serving as a complement rather than a replacement. Neutral observers see the market as one experiencing rapid expansion, but also increased scrutiny. With many brands competing for attention, consumers are becoming more selective, favoring companies that provide clear ingredient information and maintain a consistent focus on product integrity. For products like MobilityMD, standing out means continuing to align with the values of informed, wellness-conscious buyers while avoiding overreaching claims. SECTION 8: ABOUT MOBILITYMD MobilityMD was created with a clear mission — to offer a joint support supplement that prioritizes purity, ingredient transparency, and alignment with modern wellness values. The brand focuses on sourcing naturally derived components that have been historically discussed in wellness communities for their association with mobility and comfort, while avoiding unnecessary additives or synthetic fillers. Every aspect of the product, from formulation to packaging, reflects a commitment to integrity. MobilityMD positions itself not as a quick-fix solution, but as part of a balanced lifestyle that may include movement practices, mindful nutrition, and regular self-care. By maintaining a clear, educational approach to its ingredients and purpose, the brand builds trust with consumers seeking a supplement that fits seamlessly into their long-term wellness routines. In a supplement landscape crowded with exaggerated promises, MobilityMD stands out for its straightforward, ingredient-first philosophy — offering a choice for those who value both product quality and transparency. See how MobilityMD's ingredient-focused approach is resonating with today's wellness-conscious consumers. SECTION 9: CONTACT MobilityMD – Clean, Ingredient-First Joint Support – Clean, Ingredient-First Joint Support Email: [email protected] Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Investcorp: Fiscal Q4 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Investcorp Credit Management BDC, Inc. (ICMB) on Tuesday reported a loss of $434,000 in its fiscal fourth quarter. The New York-based company said it had a loss of 3 cents per share. Earnings, adjusted for investment costs, were 4 cents per share. The specialty finance company posted revenue of $4.5 million in the period.
Yahoo
2 hours ago
- Yahoo
Knightscope, Inc. (KSCP) Reports Q2 Loss, Lags Revenue Estimates
Knightscope, Inc. (KSCP) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to a loss of $2.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +17.43%. A quarter ago, it was expected that this company would post a loss of $1.47 per share when it actually produced a loss of $1.28, delivering a surprise of +12.93%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Knightscope, which belongs to the Zacks Technology Services industry, posted revenues of $2.75 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.52%. This compares to year-ago revenues of $3.2 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Knightscope shares have lost about 54.2% since the beginning of the year versus the S&P 500's gain of 8.4%. What's Next for Knightscope? While Knightscope has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Knightscope was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.08 on $2.98 million in revenues for the coming quarter and -$4.38 on $12.17 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Technology Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Coherent (COHR), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 13. This Laser and optics manufacturer is expected to post quarterly earnings of $0.93 per share in its upcoming report, which represents a year-over-year change of +52.5%. The consensus EPS estimate for the quarter has been revised 3.9% higher over the last 30 days to the current level. Coherent's revenues are expected to be $1.51 billion, up 15.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Knightscope, Inc. (KSCP) : Free Stock Analysis Report Coherent Corp. (COHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
